These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38459910)
1. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Hunter Gibble T; Abreu MT; Lee S; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Arora V; Panaccione R; Dignass A Inflamm Bowel Dis; 2024 Dec; 30(12):2245-2258. PubMed ID: 38459910 [TBL] [Abstract][Full Text] [Related]
2. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials. D'Haens G; Higgins PDR; Peyrin-Biroulet L; Sands BE; Lee S; Moses RE; Redondo I; Escobar R; Hunter Gibble T; Keohane A; Morris N; Zhang X; Arora V; Kobayashi T Inflamm Bowel Dis; 2024 Dec; 30(12):2335-2346. PubMed ID: 38271613 [TBL] [Abstract][Full Text] [Related]
3. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Gibble TH; Abreu MT; Lee SD; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Panaccione R; Dignass A Inflamm Bowel Dis; 2024 Oct; ():. PubMed ID: 39448057 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881 [TBL] [Abstract][Full Text] [Related]
5. Infliximab for maintenance of medically-induced remission in Crohn's disease. Gordon M; Sinopoulou V; Akobeng AK; Sarian A; Moran GW Cochrane Database Syst Rev; 2024 Feb; 2(2):CD012609. PubMed ID: 38372447 [TBL] [Abstract][Full Text] [Related]
6. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
7. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
9. Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study. Fischer S; Donhauser M; Cohnen S; Fietkau K; Vetter M; Grübel-Liehr M; Dietrich P; Rath T; Wilfer A; Sologub L; Krebs S; Dörje F; Nagore D; Meyer S; Neurath MF; Atreya R Therap Adv Gastroenterol; 2024; 17():17562848241301887. PubMed ID: 39619829 [TBL] [Abstract][Full Text] [Related]
10. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort. Suárez Ferrer C; Mesonero Gismero F; Caballol B; Ballester MP; Bastón Rey I; Castaño García A; Miranda Bautista J; Saiz Chumillas R; Benitez JM; Sanchez-Delgado L; López-García A; Rubin de Celix C; Alonso Abreu I; Melcarne L; Plaza Santos R; Marques-Camí M; Caballero Mateos A; Gómez Díez C; Calafat M; Galan HA; Vega Vilaamil P; Castro Senosiain B; Guerro Moya A; Rodriguez Diaz CY; Spicakova K; Manceñido Marcos N; Molina G; de Castro Parga L; Rodriguez Angulo A; Cuevas Del Campo L; Rodriguez Grau MDC; Ramirez F; Gomez Pastrana B; Gonzalez Partida I; Botella Mateu B; Peña Gonzalez E; Iyo E; Elosua Gonzalez A; Sainz Arnau E; Hernandez Villalba L; Perez Galindo P; Torrealba Medina L; Monsalve Alonso S; Olmos Perez JA; Dueñas Sadornil C; Garcia Ramirez L; Martín-Arranz MD; López Sanroman A; Fernández A; Merino Murgui V; Calviño Suárez C; Flórez-Diez P; Lobato Matilla ME; Sicilia B; Soto Escribano P; Maroto Martin C; Mañosa M; Barreiro-De Acosta M; Gastroenterol Hepatol; 2024 Dec; 47(10):502197. PubMed ID: 38710465 [TBL] [Abstract][Full Text] [Related]
12. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity? Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223 [TBL] [Abstract][Full Text] [Related]
13. Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets. Mihaylova B; Wu R; Zhou J; Williams C; Schlackow I; Emberson J; Reith C; Keech A; Robson J; Parnell R; Armitage J; Gray A; Simes J; Baigent C Health Technol Assess; 2024 Dec; 28(79):1-134. PubMed ID: 39644281 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Maksymowych WP; Lagunes-Galindo I; Bu X; Wung P; Kato K; Shmagel A; Deodhar A Arthritis Res Ther; 2024 Nov; 26(1):197. PubMed ID: 39533349 [TBL] [Abstract][Full Text] [Related]
15. Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Mease PJ; Ferrante SA; Shiff NJ; Fitzgerald TP; Chakravarty SD; Walsh JA Adv Ther; 2024 Dec; ():. PubMed ID: 39621228 [TBL] [Abstract][Full Text] [Related]
16. An evaluation of mirikizumab for the treatment of ulcerative colitis. White C; Irving PM Expert Opin Biol Ther; 2024 Nov; 24(11):1199-1206. PubMed ID: 39360778 [TBL] [Abstract][Full Text] [Related]
18. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Singh S; Loftus EV; Limketkai BN; Haydek JP; Agrawal M; Scott FI; Ananthakrishnan AN; Gastroenterology; 2024 Dec; 167(7):1307-1343. PubMed ID: 39572132 [TBL] [Abstract][Full Text] [Related]
19. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation. Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Reece D; Imrie K; Stevens A; Smith CA; Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]